Compounds > 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Page last updated: 2024-09-03

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Cancer of Prostate

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with Cancer of Prostate in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernardini, R; Fiorito, J; Marrazzo, A; Pasquinucci, L; Prezzavento, O; Ronsisvalle, G; Ronsisvalle, S; Scoto, GM; Zappalà, L1

Other Studies

1 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and Cancer of Prostate

ArticleYear
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Guinea Pigs; Haloperidol; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Phenylbutyrates; Prostatic Neoplasms; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, sigma

2011